Prague Med. Rep. 2022, 123, 35-42

https://doi.org/10.14712/23362936.2022.4

Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy

Renata Pacholczak-Madej1,2, Aleksandra Grela-Wojewoda2, Joanna Lompart2, Beata Żuchowska-Vogelgesang2, Marek Ziobro2

1Department of Anatomy, Jagiellonian University Medical College, Cracow, Poland
2Department of Clinical Oncology, The Maria Sklodowska-Curie National Research Institute of Oncology, Cracow, Poland

Received August 23, 2021
Accepted January 31, 2022

References

1. Davis, E. J., Salem, J., Young, A., Green, J. R., Ferrell, P. B., Ancell, K. K., Johnson, D. B. (2019) Hematologic complications of immune checkpoint inhibitors. Oncologist 24(5), 584–588. <https://doi.org/10.1634/theoncologist.2018-0574>
2. Dudda, M., Mann, C., Heinz, J., Schmidgen, I., Weid, F., Kühn, M., Loquai, C. (2021) Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: A case report and review to the literature. Melanoma Res. 31(1), 81–84. <https://doi.org/10.1097/CMR.0000000000000703>
3. Fardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., Hejblum, G. (2014) Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 66(9), 2613–2620. <https://doi.org/10.1002/art.38690>
4. Gambichler, T., Rached, N. A., Nowack, N., Behle, B., Susok, L. (2021) Hemophagocytic lymphohistiocytosis after initiation of combined immunotherapy for metastatic melanoma. Ann. Hematol. Oncol. 8(4), 1337.
5. Gupta, A., Weitzman, S., Abdelhaleem, M. (2008) The role of hemophagocytosis in bone marrow aspirates in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 50(2), 192–194. <https://doi.org/10.1002/pbc.21441>
6. Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., Jordan, K. (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv119–iv142 (Suppl. 4). <https://doi.org/10.1093/annonc/mdx225>
7. Henter, J. I., Horne, A., Aricó, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K., Webb, D., Winiarski, J., Janka, G. (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48(2), 124–131. <https://doi.org/10.1002/pbc.21039>
8. Henter, J. I., Chow, C. B., Leung, C. W., Lau, Y. L. (2006) Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet 367(9513), 870–873. <https://doi.org/10.1016/S0140-6736(06)68232-9>
9. Jordan, M. B., Allen, C. E., Weitzman, S., Filipovich, A. H., McClain, K. L. (2011) How I treat hemophagocytic lymphohistiocytosis. Blood 118(15), 4041–4052. <https://doi.org/10.1182/blood-2011-03-278127>
10. La Rosée, P., Horne, A., Hines, M., von Bahr Greenwood, T., Machowicz, R., Berliner, N., Birndt, S., Gil-Herrera, J., Girschikofsky, M., Jordan, M. B., Kumar, A., van Laar, J. A. M., Lachmann, G., Nichols, K. E., Ramanan, A. V., Wang, Y., Wang, Z., Janka, G., Henter, J. I. (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23), 2465–2477. <https://doi.org/10.1182/blood.2018894618>
11. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Wolchok, J. D. (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381(16), 1535–1546. <https://doi.org/10.1056/NEJMoa1910836>
12. Liu, P., Pan, X., Chen, C., Niu, T., Shuai, X., Wang, J., Liu, T. (2020) Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults. Blood 135(11), 826–833. <https://doi.org/10.1182/blood.2019003886>
13. Machowicz, R., Basak, G. (2020) How can an internal medicine specialist save a patient with hemophagocytic lymphohistiocytosis (HLH)? Pol. Arch. Intern. Med. 130(5), 431–437.
14. Mizuta, H., Nakano, E., Takahashi, A., Koyama, T., Namikawa, K., Yamazaki, N. (2020) Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review. Dermatol. Ther. 33(3), e13321.
15. Petrelli, F., Ardito, R., Borgonovo, K., Lonati, V., Cabiddu, M., Ghilardi, M., Barni, S. (2018) Haematological toxicities with immunotherapy in patients with cancer: A systematic review and meta-analysis. Eur. J. Cancer 103, 7–16. <https://doi.org/10.1016/j.ejca.2018.07.129>
16. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Ribas, A. (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521–2532. <https://doi.org/10.1056/NEJMoa1503093>
17. Sadaat, M., Jang, S. (2018) Hemophagocytic lymphohistiocytosis with immunotherapy: Brief review and case report. J. Immunother. Cancer 6(1), 49. <https://doi.org/10.1186/s40425-018-0365-3>
18. Samaran, Q., Belakebi, D., Theret, S., Becquart, O., Girard, C., Du Thanh, A., Guillot, B., Lesage, C., Dereure, O. (2020) Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases. Melanoma Res. 30(5), 519–523. <https://doi.org/10.1097/CMR.0000000000000690>
19. Stabler, S., Becquart, C., Dumezy, F., Terriou, L., Mortier, L. (2017) Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma. Melanoma Res. 27(4), 377–379. <https://doi.org/10.1097/CMR.0000000000000354>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive